AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training with weighted belts (6% of body mass)
Number of subjects: 57
Study 22404184 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg)
Number of subjects: 21
Study 22404184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20162342 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid study
Number of subjects: 223
Study 20162342 — intervention group
Group type: COMPARATOR
Intervention: Missing control group
Number of subjects: 223
Study 20162342 — intervention group
Group type: COMPARATOR
Intervention: Confound
Number of subjects: 223
Study 20162342 — intervention group
Group type: COMPARATOR
Intervention: Experimenter bias
Number of subjects: 223
Study 18026625 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Vaccine stored within the cold chain and administered in township hospitals
Number of subjects: 0
Study 18026625 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Vaccine stored out of the cold chain in villages and administered by village-based health workers
Number of subjects: 0
Study 18026625 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Same strategy as group 2, but vaccine packaged in a prefilled injection device
Number of subjects: 0
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with fixed doses of carboplatin
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <52 years
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 53-62 years
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >=63 years
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Serous histotype
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear cell histotype
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrioid histotype
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucinous histotype
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumour <= 1 cm after surgery
Number of subjects: 232
Study 16051334 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumour > 1 cm after surgery
Number of subjects: 232
Study 11585083 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol
Number of subjects: 37
Study 11585083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9700123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) therapy
Number of subjects: 122
Study 9700123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 7923999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (1 g/100 kcals to a maximum of 28 g/d)
Number of subjects: 12
Study 7923999 — intervention group
Group type: COMPARATOR
Intervention: Control (no lactulose)
Number of subjects: 12
Study 2645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic GnRH (7.5, 25, 75, and 250 ng/kg) iv at 2-h intervals after long term pulsatile GnRH administration
Number of subjects: 18
Study 2645313 — intervention group
Group type: COMPARATOR
Intervention: Endogenous GnRH-stimulated LH peaks in normal men
Number of subjects: 18
Study 2645313 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic GnRH (various doses)
Number of subjects: 18
Study 1067728 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (4.5 gums/day)
Number of subjects: 100
Study 1067728 — intervention group
Group type: COMPARATOR
Intervention: Sucrose chewing gum (4.0 gums/day)
Number of subjects: 100
Study 31806260 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR
Number of subjects: 114
Study 31806260 — intervention group
Group type: COMPARATOR
Intervention: Vascular access team presence
Number of subjects: 114
Study 31806260 — intervention group
Group type: COMPARATOR
Intervention: Caregiver presence
Number of subjects: 114
Study 31806260 — intervention group
Group type: COMPARATOR
Intervention: Peripheral intravenous access
Number of subjects: 114
Study 31587287 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT-treated PLTs
Number of subjects: 132
Study 31587287 — intervention group
Group type: COMPARATOR
Intervention: Standard PLTs
Number of subjects: 132
Study 31587287 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin and UV light-treated PLTs
Number of subjects: 132
Study 28100482 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon injection of 0.1 mL of 0.01% MMC
Number of subjects: 80
Study 28100482 — intervention group
Group type: COMPARATOR
Intervention: MMC-soaked sponges (0.02%)
Number of subjects: 80
Study 25904366 — intervention group
Group type: EXPERIMENTAL
Intervention: Active promotion with a multifaceted and repeated intervention (reminders, audit feedback, targeting local opinion leaders)
Number of subjects: 306
Study 25904366 — intervention group
Group type: COMPARATOR
Intervention: Simple information on guideline availability
Number of subjects: 306
Study 23445918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical volumetric bone density (vBMD) measurement at anterior region
Number of subjects: 80
Study 23445918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical volumetric bone density (vBMD) measurement at endocortical region
Number of subjects: 80
Study 23445918 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in cortical vBMD
Number of subjects: 80
Study 23445918 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between anterior and posterior regions
Number of subjects: 80
Study 21393433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 8021
Study 21393433 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 8021
Study 19060721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 67
Study 19060721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17032001 — intervention group
Group type: EXPERIMENTAL
Intervention: High-L spinach ('Spinner')
Number of subjects: 20
Study 17032001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-L spinach ('Springer')
Number of subjects: 20
Study 15483415 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (neutralizing antibody directed against tumor necrosis factor) at varying doses for 6, 24, or 48 hours
Number of subjects: 1000
Study 15483415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-TNF therapy)
Number of subjects: 1000
Study 10675115 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 12
Study 10675115 — intervention group
Group type: COMPARATOR
Intervention: Conventional (open) Nissen fundoplication
Number of subjects: 12
Study 9084461 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses 0.02 to 5.0 micrograms.kg-1
Number of subjects: 32
Study 9084461 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses > 2.5 micrograms.kg-1
Number of subjects: 32
Study 9084461 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) at doses > or = 1.5 micrograms.kg-1
Number of subjects: 32
Study 9084461 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 32
Study 9084461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7934973 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/d
Number of subjects: 11
Study 7934973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3278068 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg suppositories twice daily
Number of subjects: 83
Study 3278068 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1000 mg effervescent tablets three times daily
Number of subjects: 83
Study 31185775 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual kayak paddling (VKP) exercise for 60 min twice a week for 6 weeks
Number of subjects: 60
Study 31185775 — intervention group
Group type: COMPARATOR
Intervention: Control group performing home exercises
Number of subjects: 60
Study 29292274 — intervention group
Group type: EXPERIMENTAL
Intervention: SpotOn monitoring system
Number of subjects: 38
Study 26960042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation for 1 month
Number of subjects: 65
Study 26960042 — intervention group
Group type: COMPARATOR
Intervention: No cardiac rehabilitation (control group)
Number of subjects: 65
Study 24427287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-reactive phages selected using biotinylated anti-thrombin antibodies and streptavidin-coated magnetic beads.
Number of subjects: 0
Study 24427287 — intervention group
Group type: COMPARATOR
Intervention: Mock selection of the same library without thrombin.
Number of subjects: 0
Study 24427287 — intervention group
Group type: EXPERIMENTAL
Intervention: API M358R randomized at residues 352-356 (P7-P3).
Number of subjects: 0
Study 24427287 — intervention group
Group type: EXPERIMENTAL
Intervention: Most active candidates from the sixth round of screening containing DITMA and AAFVS at P7-P3.
Number of subjects: 0
Study 24427287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sequencing using the Ion Torrent platform.
Number of subjects: 0
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypotony at baseline
Number of subjects: 240
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with uveitis ≥5 years duration
Number of subjects: 240
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of ocular surgery (vitrectomy)
Number of subjects: 240
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with older age of uveitis onset (>51 years)
Number of subjects: 240
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patients
Number of subjects: 240
Study 22409563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonous eyes
Number of subjects: 240
Study 18801582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18
Study 18801582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TD)
Number of subjects: 18
Study 17617557 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G Optiva i.v. plastic cannula
Number of subjects: 120
Study 17617557 — intervention group
Group type: COMPARATOR
Intervention: Stevens' sub-Tenon's metal cannula
Number of subjects: 120
Study 15196524 — intervention group
Group type: EXPERIMENTAL
Intervention: Walker
Number of subjects: 10
Study 15196524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cane
Number of subjects: 10
Study 15196524 — intervention group
Group type: COMPARATOR
Intervention: No assistive device (hands free or holding an object)
Number of subjects: 10
Study 12905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9698949 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection spinal anaesthesia (SA)
Number of subjects: 224
Study 9698949 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA)
Number of subjects: 224
Study 10144552 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program that includes information about self-help groups
Number of subjects: 26
Study 10144552 — intervention group
Group type: COMPARATOR
Intervention: Training program that does not address self-help groups
Number of subjects: 26
Study 10144552 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential component of the training
Number of subjects: 26
Study 2145957 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 18
Study 2145957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 751811 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving intervention
Number of subjects: 20
Study 751811 — intervention group
Group type: COMPARATOR
Intervention: Insight-oriented treatment
Number of subjects: 20
Study 751811 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving therapy
Number of subjects: 20
Study 7034929 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 5 g/m2
Number of subjects: 58
Study 7034929 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 500 mg/m2
Number of subjects: 58
Study 7034929 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 50 mg/m2
Number of subjects: 58
Study 7034929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MTX
Number of subjects: 58
Study 7034929 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX (all doses)
Number of subjects: 58
Study 31790639 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program (MMRP) with mHealth app
Number of subjects: 41
Study 31790639 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 41
Study 31268828 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable RT (VAR; modulating exercise load, volume, contraction type, and interset rest interval)
Number of subjects: 20
Study 31268828 — intervention group
Group type: COMPARATOR
Intervention: Standard progressive RT [control (CON)]
Number of subjects: 20
Study 29169264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mating condition (faces encoded in the context of long-term mating relationship)
Number of subjects: 0
Study 29169264 — intervention group
Group type: COMPARATOR
Intervention: Working condition (faces encoded in the context of long-term work relationship)
Number of subjects: 0
Study 29169264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mating condition
Number of subjects: 0
Study 29169264 — intervention group
Group type: COMPARATOR
Intervention: Working condition
Number of subjects: 0
Study 25607523 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 11
Study 25607523 — intervention group
Group type: COMPARATOR
Intervention: P-TENS
Number of subjects: 11
Study 23511090 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based intervention with 4 sessions conducted in the child's primary health care office.
Number of subjects: 60
Study 23511090 — intervention group
Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 60
Study 22840253 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid medicine (only 45% of elementary school participants and 12% of high school participants)
Number of subjects: 101
Study 22840253 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported controller use
Number of subjects: 101
Study 22840253 — intervention group
Group type: EXPERIMENTAL
Intervention: No reliever medicine in home
Number of subjects: 101
Study 19938332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral functional training
Number of subjects: 48
Study 19938332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue pressure and oral diadochokinesis (pronouncing 'ka')
Number of subjects: 48
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50
Study 17312208 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 50
Study 15351752 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine influenza vaccination (injected or intranasal spray)
Number of subjects: 458
Study 15351752 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable vaccine for infants (6 months to 35 months)
Number of subjects: 458
Study 15351752 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential barriers to implementation
Number of subjects: 458
Study 12683227 — intervention group
Group type: EXPERIMENTAL
Intervention: One boiled egg per day for 8 weeks
Number of subjects: 18
Study 12683227 — intervention group
Group type: COMPARATOR
Intervention: Egg-free period
Number of subjects: 18
Study 10414674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen, 100 mg, three times a day
Number of subjects: 18
Study 10414674 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen, 1 g, three times a day
Number of subjects: 18
Study 10414674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 8649915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg dexamethasone syrup
Number of subjects: 120
Study 8649915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg dexamethasone syrup
Number of subjects: 120
Study 8649915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone syrup
Number of subjects: 120
Study 2180259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bromocriptine
Number of subjects: 64
Study 2180259 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose bromocriptine
Number of subjects: 64
Study 2180259 — intervention group
Group type: COMPARATOR
Intervention: Higher dosage regimen of bromocriptine
Number of subjects: 64
Study 2180259 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dosage of bromocriptine (5 mg-15 mg daily)
Number of subjects: 64
Study 218296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium heparin
Number of subjects: 112
Study 218296 — intervention group
Group type: COMPARATOR
Intervention: Calciparine
Number of subjects: 112
Study 31547771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 132
Study 29080466 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=12), attended three exercise sessions per week for 8 weeks
Number of subjects: 24
Study 29080466 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (n=12), advised to continue usual activities
Number of subjects: 24
Study 29080466 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=12)
Number of subjects: 24
Study 25586468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rindopepimut and standard adjuvant temozolomide chemotherapy
Number of subjects: 65
Study 23533460 — intervention group
Group type: EXPERIMENTAL
Intervention: D&G herbal capsules 1 gm/day
Number of subjects: 90
Study 23533460 — intervention group
Group type: EXPERIMENTAL
Intervention: D&G herbal capsules 2 gm/day
Number of subjects: 90
Study 23533460 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 90
Study 21942183 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 21942183 — intervention group
Group type: COMPARATOR
Intervention: Medication (Glibenclamide 2.5‐7.5 mg/time, 1‐2 times/d for 12 weeks)
Number of subjects: 80
Study 21942183 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Acupuncture and Medication
Number of subjects: 80
Study 19826060 — intervention group
Group type: EXPERIMENTAL
Intervention: dexlansoprazole MR 90 mg
Number of subjects: 40
Study 19826060 — intervention group
Group type: EXPERIMENTAL
Intervention: dexlansoprazole MR 300 mg
Number of subjects: 40
Study 19826060 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg
Number of subjects: 40
Study 19826060 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 16717144 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 16
Study 16717144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14762784 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene‐covered stent (group 1; 39 patients)
Number of subjects: 80
Study 14762784 — intervention group
Group type: COMPARATOR
Intervention: Usual uncovered prosthesis (group 2; 41 patients)
Number of subjects: 80
Study 14762784 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene‐covered stent (group 1)
Number of subjects: 80
Study 14762784 — intervention group
Group type: COMPARATOR
Intervention: Usual uncovered prosthesis (group 2)
Number of subjects: 80
Study 14562531 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 64
Study 14562531 — intervention group
Group type: COMPARATOR
Intervention: Silverex
Number of subjects: 64
Study 9701429 — intervention group
Group type: EXPERIMENTAL
Intervention: flutter
Number of subjects: 22
Study 9701429 — intervention group
Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 22
Study 7829780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg body weight per min, n = 10)
Number of subjects: 20
Study 7829780 — intervention group
Group type: COMPARATOR
Intervention: MS-857 (15 mg, n = 10)
Number of subjects: 20
Study 2194417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (neomycin and erythromycin)
Number of subjects: 169
Study 2194417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 169
Study 2194417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral and intravenous antibiotics
Number of subjects: 169
Study 2194417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 169
Study 369735 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray (0.025% solution, 200 microgram daily dosage)
Number of subjects: 50
Study 369735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive aqueous vehicle)
Number of subjects: 50
Study 31485869 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-infarct volume increase
Number of subjects: 132
Study 31485869 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-penumbra volume increase
Number of subjects: 132
Study 31485869 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of recanalization
Number of subjects: 132
Study 31485869 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to infarct at 7 days
Number of subjects: 132